DRE’s Medical Strategy Advisory Board (MSAB) advises DRE on the convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes and the MSAB is a steering committee governance Board to ensure that our mission is achieved.

Ameet Nathwani, MD, is Chairman of DRE’s Medical Strategy Advisory Board (MSAB), which will initially include 5 members.

Ameet Nathwani, MD

Chairman, Medical Strategic Advisory Board

With more than 25 years of experience in the pharmaceutical industry, Dr. Nathwani was most recently an Executive Committee member at Sanofi AG, as Chief Medical Officer (CMO), Head of Medical and Chief Digital Officer (CDO), responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.

Dr. Nathwani began his industry career in 1994 when he joined Glaxo Group Research where he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and the US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real-World Evidence Center of Excellence and Digital Medicine capability. Dr. Nathwani is also a Director of the Medical Affairs Professional Society (MAPS).

Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.